Journal articles on the topic 'Finch, Pruyn and Company, Inc'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 15 journal articles for your research on the topic 'Finch, Pruyn and Company, Inc.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Burmester, G. R., D. Aletaha, J. Pope, Y. Tanaka, P. Durez, A. Gomez-Centeno, A. Pechonkina, et al. "THU0194 CHARACTERISATION OF DEPTH OF RESPONSE, INCLUDING 50% IMPROVEMENT IN ACR COMPONENTS AT WEEK 12 AND REMISSION AT WEEK 24, FOLLOWING TREATMENT WITH FILGOTINIB COMPARED WITH METHOTREXATE OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 316.1–317. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2236.
Full textCombe, B., A. Kivitz, Y. Tanaka, D. Van der Heijde, J. A. Simon-Campos, H. S. B. Baraf, U. Kumar, et al. "THU0198 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 320–21. http://dx.doi.org/10.1136/annrheumdis-2020-eular.276.
Full textKivitz, A., Y. Tanaka, S. Lee, L. Ye, H. Hu, R. Besuyen, and B. Combe. "FRI0128 FILGOTINIB PROVIDED RAPID AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL STATUS, PAIN, HEALTH-RELATED QUALITY OF LIFE, AND FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM THE FINCH 1 STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 645.2–646. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2882.
Full textTaylor, P. C., J. Liu, L. Zhuo, Y. Tian, T. Snyder, C. Kim, P. Kheradpour, K. Drake, S. Kim, and R. E. Hawtin. "OP0100 MOLECULAR PROFILING OF PERIPHERAL IMMUNE CELL SUBSETS IN PATIENTS WITH RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 65.2–65. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3967.
Full textWalker, D., T. Takeuchi, B. Bartok, S. Rao, I. H. Lee, R. Besuyen, J. E. Gottenberg, and M. C. Genovese. "FRI0139 FILGOTINIB PROVIDED RAPID AND SUSTAINED RELIEF OF PAIN AND FATIGUE AND IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DMARDS: RESULTS FROM THE FINCH 2 STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 652–53. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2901.
Full textWinthrop, K., M. H. Buch, J. Curtis, G. R. Burmester, D. Aletaha, K. Amano, A. Pechonkina, et al. "POS0092 HERPES ZOSTER IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 255.1–256. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1408.
Full textCombe, B., T. Matsubara, A. Pechonkina, Y. Tan, Z. Yin, J. Hong, R. Besuyen, A. Gomez-Centeno, and M. H. Buch. "POS0657 GEOGRAPHIC VARIATION OF SAFETY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 569.2–570. http://dx.doi.org/10.1136/annrheumdis-2021-eular.643.
Full textGenovese, M. C., K. Winthrop, Y. Tanaka, T. Takeuchi, A. Kivitz, F. Matzkies, L. Ye, et al. "THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 324–25. http://dx.doi.org/10.1136/annrheumdis-2020-eular.267.
Full textGottenberg, J. E., M. H. Buch, R. Caporali, G. C. Wright, T. Takeuchi, K. Kalunian, A. Pechonkina, et al. "THU0204 A SUBGROUP ANALYSIS OF LOW DISEASE ACTIVITY AND REMISSION FROM PHASE 3 STUDY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARDS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 326–27. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2237.
Full textBuch, M. H., T. Matsubara, B. Combe, A. Pechonkina, Y. Tan, Z. Yin, J. Hong, R. Besuyen, and A. Gomez-Centeno. "POS0658 GEOGRAPHIC VARIATION OF EFFICACY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 570–71. http://dx.doi.org/10.1136/annrheumdis-2021-eular.648.
Full textGottenberg, J. E., G. R. Burmester, K. Van Beneden, C. Watson, I. Seghers, V. Rajendran, L. Dagna, and M. H. Buch. "POS0513 SAFETY OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: ANALYSIS OF LYMPHOCYTES IN THE LONG-TERM EXTENSION FINCH 4 STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 512–13. http://dx.doi.org/10.1136/annrheumdis-2022-eular.888.
Full textWinthrop, K., D. Aletaha, R. Caporali, Y. Tanaka, T. Takeuchi, P. Van Hoek, P. J. Stiers, et al. "POS0844 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WITH A MAXIMUM EXPOSURE OF 8.3 YEARS." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 721–22. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1553.
Full textWalker, David, Kevin Winthrop, Mark C. Genovese, Bernard G. Combe, Yoshiya Tanaka, Alan Kivitiz, Franziska Matzkies, et al. "O09 Pooled safety analyses from Phase 3 studies of filgotinib in patients with RA." Rheumatology 59, Supplement_2 (April 1, 2020). http://dx.doi.org/10.1093/rheumatology/keaa110.008.
Full textHerkness, Jenna, and Matthew Sims. "1839. Social Determinants of Health in Extended Spectrum Beta-Lactamase Carriage in the Urine – The Influence of Race, Ethnicity and Sex in the Outpatient Setting." Open Forum Infectious Diseases 10, Supplement_2 (November 27, 2023). http://dx.doi.org/10.1093/ofid/ofad500.1668.
Full textGeurtsen, Jeroen, Joachim Doua, Luis Martinez-Martinez, Patricia Ibarra de Palacios, Jeff Powis, Matthew Sims, Peter Hermans, et al. "2465. O-serotype Distribution of Escherichia coli Causing Invasive Disease in Tertiary Care Hospital Patients." Open Forum Infectious Diseases 10, Supplement_2 (November 27, 2023). http://dx.doi.org/10.1093/ofid/ofad500.2083.
Full text